#ASCO21: Novartis gears up for CAR-T fight with Gilead in follicular lymphoma — and safety could define the battle
Since winning the first CAR-T approval in the US back in 2017, Novartis has been hard at work expanding the reach of its blockbuster cancer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
